Methylphenidate hydrochloride extended-release - RVL Pharmaceuticals
Alternative Names: Methylphenidate HCl ER tablets - Osmotica Pharmaceuticals; RELEXXIILatest Information Update: 22 Dec 2023
At a glance
- Originator RVL Pharmaceuticals
- Class Behavioural disorder therapies; Neuroprotectants; Nootropics; Phenylacetates; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Adrenergic uptake inhibitors; Central nervous system stimulants; Dopamine release stimulants; Monoamine oxidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
Most Recent Events
- 19 Dec 2023 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In the elderly, In adults) in USA (PO)
- 23 Jun 2022 Registered for Attention-deficit hyperactivity disorder (In adolescents, In children, In the elderly, In adults) in USA (PO)
- 19 Jan 2022 Osmotica Pharmaceuticals is now called RVL Pharmaceuticals